DESENTUM
Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.
DESENTUM
Industry:
Biotechnology Pharmaceutical
Founded:
2011-01-01
Address:
Espoo, Southern Finland, Finland
Country:
Finland
Website Url:
http://www.desentum.fi
Total Employee:
1+
Status:
Active
Contact:
+358500512934
Email Addresses:
[email protected]
Total Funding:
17.69 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Tag Manager Content Delivery Network Apache Euro US Privacy User Signal Mechanism YouTube Pound Sterling Japanese Yen
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Advaxis
Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
OncoHost
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Current Employees Featured
Founder
Investors List
Springvest
Springvest investment in Venture Round - Desentum
European Innovation Council
European Innovation Council investment in Grant - Desentum
Springvest
Springvest investment in Series A - Desentum
VTT Ventures
VTT Ventures investment in Series A - Desentum
Sto-Rahoitus
Sto-Rahoitus investment in Series A - Desentum
Luxembourgian ACME Investments
Luxembourgian ACME Investments investment in Series A - Desentum
Cascara Ventures
Cascara Ventures investment in Series A - Desentum
Official Site Inspections
http://www.desentum.fi
- Host name: fi-f2.seravo.net
- IP address: 95.217.44.205
- Location: Finland
- Latitude: 60.1717
- Longitude: 24.9349
- Timezone: Europe/Helsinki
More informations about "Desentum"
Desentum
Desentum was founded in 2011 as a spin-off from VTT technical Research Centre of Finland, following scientific discoveries made by research groups at the University of Eastern Finland …See details»
Allergen immunotherapy | Desentum
Desentum’s mission is to expand the use of allergen immunotherapy (AIT) world-wide by introducing novel, effective, safe and patient-friendly AIT products that are well-documented and approved by the regulatory authorities. Our lead …See details»
Desentum - Crunchbase Company Profile & Funding
Contact Email [email protected]; Phone Number +358500512934; Desentum is a research-oriented biopharmaceutical company specialized in developing novel …See details»
Desentum Oy
Desentum perustettiin vuonna 2011 Teknologian tutkimuskeskus VTT:n spin-off-yrityksenä. VTT:llä ja Itä-Suomen yliopistolla toimivat tutkimusryhmät onnistuivat selvittämään ennestään tuntemattomia mekanismeja, jotka vaikuttavat …See details»
Desentum 2025 Company Profile: Valuation, Funding
Desentum General Information Description. Developer of a biopharmaceutical platform designed to develop novel types of allergen immunotherapy products …See details»
Desentum Oy, Financial Info, Board and Management, …
Desentum Oy ℗ Return To Hit List Organization Number: 2425894-6 . Company; Insights; CONTACT INFORMATION Phone: 358 50 0512934 Address: 02150, Espoo Website: …See details»
Desentum’s immunotherapy can change the treatment …
Mar 27, 2024 In Desentum’s solution, the desensitisation process is significantly quicker and more efficient compared to the currently used practices. Desentum’s goal is to reduce the treatment time for pollen allergies from years to just a few …See details»
Desentum Company Profile - Office Locations, Competitors ... - Craft
Desentum has 5 employees across 2 locations. See insights on Desentum including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Desentum Oy - suomenbioteollisuus.fi
Desentum Oy Innopoli 2 Tekniikantie 14 02150 Espoo. Desentum is a clinical-stage, research-oriented biopharmaceutical company specialized in developing novel types of allergen immunotherapy products that are based on switching …See details»
Desentum - VentureRadar
" Desentum is a clinical-stage biopharmaceutical company focused on the development of novel allergen immunotherapy (AIT) products. Their mission is to make AIT more accessible globally …See details»
Desentum - The Org
Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system. ... desentum.fi/en. Headquarters. Espoo, Finland. Industries. …See details»
Desentum - 2025 Company Profile, Funding & Competitors - Tracxn
Feb 27, 2025 Desentum - Developing novel types of allergen immunotherapy products (allergy vaccines). Raised a total funding of $26.7M over 8 rounds from 6 investors. Founded by Pekka …See details»
☑️Desentum Oy — Consulting Organization from
Desentum Oy — Consulting Organization from Finland with 51-200 employees, has experience with Horizon 2020 (2014 - 2020), it`s involved in Health, Research sectors.See details»
Desentum Company Information - Funding, Investors, and More
Website: https://desentum.fi; Business model: b2b Company size: 1 - 11 employees Headquarters: Espoo, Finland Founded: 2011 ... Funding. Funding series. Funding Series …See details»
Allergen immunotherapy - Desentum
Desentum ’s hypoallergens are designed to induce a protective immunological response without compromising safety during treatment: Targeted modifications in the allergen protein to reduce …See details»
Desentum - Funding, Financials, Valuation & Investors - Crunchbase
Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system. New. Resources. Advanced Search. Start Free Trial . ... How much …See details»
Desentum raises €12 million for allergy vaccines - vaccinenation.org
In February 2024, Finnish biopharmaceutical company Desentum announced that it had raised €12 million in a funding round organised by investment company Springvest Oyj in January …See details»
Desentum - yritystiedot, päättäjät, taloustiedot | Finder
Finder kertoo Desentum yrityksestä kaiken olennaisen. Tutki yritystietoja, taloustietoja, päättäjätietoja ja tulosta. Finder Pro. ... www.desentum.fi. Lisää suosikkeihin compare_arrows …See details»
Desentumin tieteellinen läpimurto – suomalainen biolääkeyritys …
Jan 22, 2024 Desentum on ensimmäisenä maailmassa määrittänyt maapähkinäallergeenin ja IgE-vasta-aineen muodostaman immunokompleksin rakenteen ja jättänyt löydöstään …See details»
Desentum received clinical trial approval from Health Canada
Sep 14, 2023 The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a clinical study on DM-101PX, an investigational preparation …See details»